AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6784566
Drug: Nitroglycerin ointment
RxNorm normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin ointment (2%, 15 mg) administered every 6 hours for 48 hours
Trial: 6784566
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment administered every 6 hours for 48 hours
Trial: 29064909
Drug: Pexacerfont (300,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pexacerfont (300, 200, and 100 mg/day in the first, second, and third week, respectively)
Trial: 16336673
Drug: Inhaled dry
RxNorm normalized name: Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled dry powder mannitol (M)
Trial: 9633846
Drug: Paclitaxel (135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (135 mg/m2, 24‐hour infusion) plus cisplatin (75 mg/m2)
Trial: 9633846
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m2, 3‐hour infusion) plus carboplatin dosed to an area under curve of 7.5
Trial: 9633846
Drug: New agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New agents (topotecan, gemcitabine, oral etoposide, encapsulated doxorubicin)
Trial: 29938621
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ω‐3 fatty acids (2500 mg) plus nano‐curcumin (80 mg)
Trial: 29938621
Drug: ω‐3 (2500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 (2500 mg)
Trial: 29938621
Drug: Nano-curcumin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nano-curcumin (80 mg)
Trial: 29938621
Drug: Control (ω‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (ω‐3 and nano‐curcumin placebo included oral paraffin oil)
Trial: 22733286
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B - individual adjustments of treatment sphere and treatment cylinder
Trial: 12095666
Drug: Methadone (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (standard prison treatment)
Trial: 8123862
Drug: Bu/Cy2 regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bu/Cy2 regimen with monoclonal antibody-purged bone marrow
Trial: 8123862
Drug: Cy/fTBI regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cy/fTBI regimen with monoclonal antibody-purged bone marrow
Trial: 2775611
Drug: Sodium diclofenac
RxNorm normalized name: Diclofenac Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium diclofenac (50 mg) dissolved in homogenized meal (C)
Trial: 2775611
Drug: Sodium diclofenac
RxNorm normalized name: Diclofenac Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium diclofenac (50 mg) dissolved in phosphate buffer pH 7.5 (B)
Trial: 2775611
Drug: Sodium diclofenac
RxNorm normalized name: Diclofenac Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium diclofenac (50 mg) dissolved in water (A)
Trial: 27639439
Drug: Hyaluronan (HA)
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronan (HA) injections
Trial: 25889091
Drug: Glucose-lowering oral
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-lowering oral agents
Trial: 23462724
Drug: AGI004 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGI004 4 mg then 8 mg per 24 h transdermal patch
Trial: 23462724
Drug: AGI004 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGI004 8 mg per 24 h transdermal patch
Trial: 23462724
Drug: AGI004 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGI004 4 mg per 24 h transdermal patch
Trial: 21297494
Drug: POM3 (omega-3-acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POM3 (omega-3-acid ethyl esters, 4 g/day)
Trial: 18304964
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HD-CT) with cyclophosphamide (1500 mg/m2), thiotepa (150 mg/m2), and mitoxantrone (10 mg/m2) for four consecutive days followed by stem cell transplantation
Trial: 18304964
Drug: Standard-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose chemotherapy (SD-CT) with three cycles of CMF (cyclophosphamide 500 mg/m2, methotrexate 40 mg/m2, 5-fluorouracil 600 mg/m2)
Trial: 15705206
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid (budesonide 400 mug)
Trial: 12074350
Drug: Cilazapril (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (2.0 mg/day)
Trial: 12074350
Drug: Atenolol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (25 mg/day)
Trial: 7486038
Drug: edrophonium (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: edrophonium (1 mg/kg)
Trial: 548840
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg twice a day)
Trial: 548840
Drug: Adrenalin (epinephrine
RxNorm normalized name: EPINEPHRINE 16 ug in 1 mL INTRAVENOUS INJECTION [Adrenalin (epinephrine in sodium chloride)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenalin (epinephrine eyedrops twice a day)
Trial: 20446856
Drug: Tiotropium therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium therapy
Trial: 15592731
Drug: Modafinil 400
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil 400 mg/d
Trial: 11106916
Drug: DHEA replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA replacement (50 mg/day for 6 months)
Trial: 9322326
Drug: Differentiated, individual‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Differentiated, individual‐based treatment program
Trial: 3019212
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg per day
Trial: 3019212
Drug: Altizide 15
RxNorm normalized name: althiazide 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Altizide 15 mg combined with Spironolactone 25 mg
Trial: 10071518
Drug: diphenhydramine 50
RxNorm normalized name: diphenhydrAMINE 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diphenhydramine 50 mg
Trial: 16168682
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg glucosamine sulfate
Trial: 16168682
Drug: 1,500 mg
RxNorm normalized name: garlic 1,500 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,500 mg glucosamine sulfate
Trial: 16168682
Drug: 3,000 mg
RxNorm normalized name: ascorbic acid/minerals 3,000 mg ORAL POWDER IN PACKET (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3,000 mg glucosamine sulfate
Trial: 12211218
Drug: Ocular instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular instillation of carteolol (0.8 mg)
Trial: 12211218
Drug: Nasal instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal instillation of carteolol (0.8 mg)
Trial: 10770458
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (20 mg/kg body weight) as adjunct to neuroleptic medication
Trial: 3520988
Drug: OKT3 monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKT3 monoclonal antibody
Trial: 14621840
Drug: ALG (antilymphocyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALG (antilymphocyte globulin) polyclonal antibody
Trial: 3909732
Drug: Vaginally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginally administered terbutaline sulphate (0.1 mg in 1 ml cellulose gel)
Trial: 3909732
Drug: Vaginally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginally administered terbutaline sulphate (5-g medicated vaginal polymer ring containing 10% terbutaline sulphate)
Trial: 3909732
Drug: Vaginally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginally administered terbutaline
Trial: 23958607
Drug: Integrated body‐mind‐spirit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated body‐mind‐spirit group intervention (4 sessions, >3 hours each, once per week) + routine hospital treatment
Trial: 23958607
Drug: Routine hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine hospital treatment only
Trial: 7961198
Drug: 500 mg/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/L CaCO3
Trial: 7961198
Drug: 200 mg/L
RxNorm normalized name: cimetidine in 0.9 % NaCl 1,200 mg/L INTRAVEN INTRAVENOUS SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/L ofloxacin
Trial: 7961198
Drug: 2000 mg/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg/L ciprofloxacin with 5000 mg/L CaCO3
Trial: 7961198
Drug: 200 mg/L
RxNorm normalized name: cimetidine in 0.9 % NaCl 1,200 mg/L INTRAVEN INTRAVENOUS SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/L ofloxacin with 5000 mg/L CaCO3
Trial: 7961198
Drug: 400 mg/L
RxNorm normalized name: theophylline in dextrose 5 % 400 mg/L INTRAVEN INTRAVENOUS SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/L ciprofloxacin with 5000 mg/L CaCO3
Trial: 2975595
Drug: Doxazosin 8
RxNorm normalized name: doxazosin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 8 mg daily
Trial: 29892042
Drug: Exosomes from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exosomes from fasting morning plasma samples after 3 months of CPAP therapy (n=24)
Trial: 26718897
Drug: Community-based educational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based educational intervention led by lay health workers including monthly distribution of Iron and folic acid (IFA) supplements and five monthly counseling sessions.
Trial: 26718897
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (control group) including distribution of IFA to mothers of anemic children without education and counseling support.
Trial: 24077193
Drug: Cervical epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical epidural injections with lidocaine 0.5% preservative-free, 5 mL (Group I)
Trial: 24077193
Drug: Cervical epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical epidural injections with 0.5% preservative-free lidocaine mixed with 1 mL or 6 mg of non-particulate betamethasone (Group II)
Trial: 24077193
Drug: Cervical epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical epidural injections with lidocaine 0.5% preservative-free (Group I)
Trial: 12450708
Drug: Flt3 ligand
RxNorm normalized name: Allogeneic natural killer (NK) cells derived from CD34+ human placental stem/progenitor cells. The cells are expanded and differentiated in the presence of cytokines including thrombopoietin, SCF, Flt3 ligand, IL-7, IL-15 and IL-2 to generate the NK cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flt3 ligand (20 microg/kg, maximum 1500 microg) administered SQ every day for 1 week
Trial: 2657199
Drug: Other glaucoma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other glaucoma drugs
Trial: 25336703
Drug: Cisplatin ≤
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin ≤ 850 mg
Trial: 18569006
Drug: 3.0 g
RxNorm normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 g NS day(‐1) (high dose, HD)
Trial: 18569006
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g NS day(‐1) (low dose, LD)
Trial: 16222401
Drug: D-hormone serum
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-hormone serum concentrations (high)
Trial: 16222401
Drug: D-hormone serum
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-hormone serum concentrations (low)
Trial: 16222401
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake >= 512 mg/day
Trial: 16222401
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake < 512 mg/day
Trial: 16222401
Drug: D-hormone serum
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-hormone serum concentrations
Trial: 10496143
Drug: Melatonin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (10 mg) administered at 13:00 hr for 5 consecutive days during the late follicular and early luteal phases of the menstrual cycle.
Trial: 7795515
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg atracurium
Trial: 7795515
Drug: 0.07 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.07 mg/kg vecuronium
Trial: 2385209
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ASS daily
Trial: 2385209
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ASS daily
Trial: 29953014
Drug: Ashwagandha extract
RxNorm normalized name: ashwagandha extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ashwagandha extract (daily supplement for 42 days)
Trial: 29953014
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily supplement for 42 days)
Trial: 27590106
Drug: Topical Dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Dexamethasone (.5 mg/mL), rinsed with 5 mL for 5 minutes, 4 times a day, for 4 weeks
Trial: 27590106
Drug: Topical Tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Tacrolimus (.5 mg/mL), rinsed with 5 mL for 5 minutes, 4 times a day, for 4 weeks
Trial: 27590106
Drug: Topical Tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Tacrolimus
Trial: 12117085
Drug: T/APAP 75/650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T/APAP 75/650 mg (2 tablets)
Trial: 12117085
Drug: HC/APAP (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HC/APAP (1 tablet)
Trial: 12117085
Drug: T/APAP 75/650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T/APAP 75/650 mg (1 tablet)
Trial: 7518766
Drug: Intravenous or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous or intramuscular ceftriaxone 50 mg/kg/day for 2 days followed by oral cefetamet pivoxil 20 mg/kg/day in 2 divided doses to complete 7 days of treatment (arm A)
Trial: 7518766
Drug: Ceftriaxone 50
RxNorm normalized name: ceftriaxone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 50 mg/kg/day for 1 day followed by 6 days' treatment with cefetamet pivoxil 20 mg/kg/day (arm B)
Trial: 2923962
Drug: 4 x
RxNorm normalized name: Mepilex AG 4 x 4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 10 mg test tablets, 1 x 40 mg test tablet, 4 x 10 mg Inderal tablets, 40 mg of propranolol HCl in solution (Study I)
Trial: 2923962
Drug: 1 x
RxNorm normalized name: Black Cohosh 1 X Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 80 mg test tablet, 1 x 80 mg Inderal tablet, 80 mg of propranolol HCl in solution (Study II)
Trial: 31212044
Drug: Specific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific treatment
Trial: 31593484
Drug: FOLFOX (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, and fluorouracil bolus 400 mg/m2 on day 1, fluorouracil infusion 2,400 mg/m2 for 46 hours)
Trial: 31593484
Drug: FL (fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FL (fluorouracil 380 mg/m2 and leucovorin 20 mg/m2)
Trial: 25218876
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice (100 mL before each dialysis session)
Trial: 25218876
Drug: Pomegranate extract
RxNorm normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate extract (1,050 mg daily)
Trial: 21793817
Drug: Nontraditional practice
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nontraditional practice (problems presented in a nontraditional format, e.g., 17 = 9 + 8)
Trial: 21793817
Drug: Traditional practice
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional practice (problems presented in the traditional 'operations on left side' format, e.g., 9 + 8 = 17)
Trial: 8915800
Drug: Topical steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroids
Trial: 15305956
Drug: Short nitroglycerine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short nitroglycerine test (15 minutes passive phase + 400 microg sublingual nitroglycerin for 15 minutes)
Trial: 15305956
Drug: Conventional isoproterenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional isoproterenol protocol (30 minutes passive phase + 20 minutes drug-challenge phase)
Trial: 8437633
Drug: HA-1A (Centoxin),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA-1A (Centoxin), a human anti-endotoxin monoclonal IgM antibody
Trial: 30157880
Drug: Anakinra, self-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra, self-administered daily by subcutaneous injection over 8 weeks
Trial: 27125363
Drug: Lopinavir/ritonavir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir plus lamivudine (dual-therapy)
Trial: 27125363
Drug: Lopinavir/ritonavir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir plus two NRTIs (triple-therapy)
Trial: 27125363
Drug: Lopinavir/ritonavir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir plus lamivudine (dual-therapy) with discontinuation of tenofovir-DF
Trial: 27125363
Drug: Lopinavir/ritonavir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir plus two NRTIs (triple-therapy) with discontinuation of abacavir
Trial: 27125363
Drug: Lopinavir/ritonavir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir plus lamivudine (dual-therapy) and Lopinavir/ritonavir plus two NRTIs (triple-therapy)
Trial: 20398185
Drug: PK measurements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PK measurements for dose tailoring of FVIII
Trial: 10475187
Drug: Intra-arterial infusions
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusions of L-arginine
Trial: 10475187
Drug: Intra-arterial infusions
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusions of sodium nitroprusside
Trial: 27633636
Drug: Family-led rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-led rehabilitation intervention for stroke patients, details on dosage and duration not specified.
Trial: 25056464
Drug: Oral dydrogesterone
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dydrogesterone (group A, n=51)
Trial: 22772417
Drug: Home-based rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based rehabilitation management (treatment group)
Trial: 20117625
Drug: Nonoperative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative therapy (control)
Trial: 16836502
Drug: Benzyl benzoate
RxNorm normalized name: Benzyl Benzoate
DrugBank: Benzyl benzoate (DB00676)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzyl benzoate (BB) lotion for 5 days
Trial: 2702160
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy by dental school assistants (experimental group)
Trial: 4311188
Drug: Intravenous methylamphetamine
RxNorm normalized name: dimethylamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous methylamphetamine
Trial: 4311188
Drug: Oral dexamphetamine
RxNorm normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamphetamine
Trial: 3187466
Drug: Continuous ultrasound
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous ultrasound treatment
Trial: 28632555
Drug: Sham ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ultrasound treatment
Trial: 19857039
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy (radiotherapy or radiochemotherapy)
Trial: 15818076
Drug: Nonselective nonsteroidal
RxNorm normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonselective nonsteroidal anti‐inflammatory drug
Trial: 11910256
Drug: Thioridazine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine (200 mg, bid)
Trial: 11910256
Drug: Risperidone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (3 mg, bid)
Trial: 11910256
Drug: Haloperidol (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (7.5 mg, bid)
Trial: 11910256
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three coadministered therapies
Trial: 11910256
Drug: Quetiapine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine monotherapy transitioning to coadministration